{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:06:20Z","timestamp":1789103180812,"version":"build-2803163510"},"reference-count":49,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"crossref","award":["075-15-2024-548"],"award-info":[{"award-number":["075-15-2024-548"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>GLP-1 receptor (GLP-1R) agonists are increasingly investigated in epilepsy, but antiseizure activity, neuroprotection, and disease modification are distinct therapeutic claims. This critical narrative review with structured evidence mapping separates these claims across 21 preclinical primary publications and eight human studies identified through 6 August 2026. Selected GLP-1R-related interventions show antiseizure and anti-kindling signals, but effects vary across compounds, models, treatment timing, and seizure types; null and pro-seizure findings in absence epilepsy preclude a uniform class-wide antiseizure effect, and concurrent anti-kindling does not establish antiepileptogenesis. Neuroprotective evidence is broader, although direct neuronal or tissue preservation is demonstrated only in selected studies; many findings remain biomarker-based, and seizure reduction may itself lessen downstream injury. Evidence for durable disease modification remains suggestive rather than established. Causal support is strongest at the receptor level, whereas most downstream synaptic, inflammatory, glial, oxidative, and mitochondrial evidence remains associative. Semaglutide has high translational relevance but remains directly under-tested in epilepsy, and human evidence is predominantly observational or safety-oriented and does not establish therapeutic epilepsy efficacy. Progress requires chronic epilepsy studies with longitudinal EEG\/video-EEG and baseline seizure burden, post-insult designs controlling initial-insult severity and assessing persistence after withdrawal, and linked pharmacokinetic, target-engagement, and causal mechanistic testing.<\/jats:p>","DOI":"10.3390\/ijms27188036","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:01:56Z","timestamp":1788966116000},"page":"8036","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 Receptor Agonists in Epilepsy: Separating Evidence for Antiseizure Activity, Neuroprotection, and Disease Modification"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5686-2871","authenticated-orcid":false,"given":"Yuliy A.","family":"Gorgul","sequence":"first","affiliation":[{"name":"Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, 194223 Saint-Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-0647","authenticated-orcid":false,"given":"Aleksey V.","family":"Zaitsev","sequence":"additional","affiliation":[{"name":"Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, 194223 Saint-Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE Official Report: A Practical Clinical Definition of Epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev-med-050522-034458","article-title":"Advances in Therapy for Refractory Epilepsy","volume":"76","author":"Jehi","year":"2025","journal-title":"Annu. Rev. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13311-014-0257-2","article-title":"Past and Present Definitions of Epileptogenesis and Its Biomarkers","volume":"11","author":"Engel","year":"2014","journal-title":"Neurotherapeutics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/med.22070","article-title":"Incretin-Based Therapies for the Management of Cardiometabolic Disease in the Clinic: Past, Present, and Future","volume":"45","author":"Psaltis","year":"2025","journal-title":"Med. Res. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/pr.115.011395","article-title":"Glucagon-Like Peptide-1 and Its Class B G Protein\u2013Coupled Receptors: A Long March to Therapeutic Successes","volume":"68","author":"Donnelly","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s42255-025-01263-4","article-title":"Incretin-Based Therapeutics for the Treatment of Neurodegenerative Diseases","volume":"7","author":"Vear","year":"2025","journal-title":"Nat. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1134\/S0006297926600857","article-title":"Metabolic Reprogramming of Astrocytes and Microglia as a Driver and Therapeutic Target in Epileptogenesis","volume":"91","author":"Zakharova","year":"2026","journal-title":"Biochemistry (Moscow)"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like Peptide-1 Receptor Is Involved in Learning and Neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2019.02.028","article-title":"Inhibitory Effects of Glucagon-like Peptide-1 Receptor on Epilepsy","volume":"511","author":"Wen","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.brainresbull.2019.08.001","article-title":"Evaluation of the Effects of Liraglutide on the Development of Epilepsy and Behavioural Alterations in Two Animal Models of Epileptogenesis","volume":"153","author":"Citraro","year":"2019","journal-title":"Brain Res. Bull."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e214509","DOI":"10.1212\/WNL.0000000000214509","article-title":"Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes","volume":"106","author":"Cheng","year":"2026","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102726","DOI":"10.1016\/j.eclinm.2024.102726","article-title":"12-Month Neurological and Psychiatric Outcomes of Semaglutide Use for Type 2 Diabetes: A Propensity-Score Matched Cohort Study","volume":"74","author":"Koychev","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE Classification of the Epilepsies: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"108246","DOI":"10.1016\/j.yebeh.2021.108246","article-title":"Exendin-4 Increases Absence-like Seizures and Anxiety-Depression-like Behaviors in WAG\/Rij Rats","volume":"123","author":"Aygun","year":"2021","journal-title":"Epilepsy Behav."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1528-1167.2011.03391.x","article-title":"Identification of New Epilepsy Treatments: Issues in Preclinical Methodology","volume":"53","author":"Galanopoulou","year":"2012","journal-title":"Epilepsia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1124\/pr.110.003046","article-title":"Prevention or Modification of Epileptogenesis after Brain Insults: Experimental Approaches and Translational Research","volume":"62","author":"Brandt","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin Therapies: Highlighting Common Features and Differences in the Modes of Action of Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3892\/ijmm.2021.5052","article-title":"Semaglutide Attenuates Seizure Severity and Ameliorates Cognitive Dysfunction by Blocking the NLR Family Pyrin Domain Containing 3 Inflammasome in Pentylenetetrazole-kindled Mice","volume":"48","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fphar.2020.00136","article-title":"The Glucagon-Like Peptide-1 Analogue Liraglutide Reduces Seizures Susceptibility, Cognition Dysfunction and Neuronal Apoptosis in a Mouse Model of Dravet Syndrome","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"176903","DOI":"10.1016\/j.ejphar.2024.176903","article-title":"Targeting Microglial GLP1R in Epilepsy: A Novel Approach to Modulate Neuroinflammation and Neuronal Apoptosis","volume":"981","author":"Zhang","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"175098","DOI":"10.1016\/j.ejphar.2022.175098","article-title":"Liraglutide Chronic Treatment Prevents Development of Tolerance to Antiseizure Effects of Diazepam in Genetically Epilepsy Prone Rats","volume":"928","author":"Tallarico","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11010-016-2678-1","article-title":"Neurochemical Modulation Involved in the Beneficial Effect of Liraglutide, GLP-1 Agonist on PTZ Kindling Epilepsy-Induced Comorbidities in Mice","volume":"415","author":"Koshal","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s11064-016-1890-4","article-title":"Effect of Liraglutide on Corneal Kindling Epilepsy Induced Depression and Cognitive Impairment in Mice","volume":"41","author":"Koshal","year":"2016","journal-title":"Neurochem. Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hussein, A.M., Eldosoky, M., El-Shafey, M., El-Mesery, M., Abbas, K.M., Ali, A.N., Helal, G.M., and Abulseoud, O.A. (2019). Effects of GLP-1 Receptor Activation on a Pentylenetetrazole-Kindling Rat Model. Brain Sci., 9.","DOI":"10.3390\/brainsci9050108"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.biopha.2018.10.066","article-title":"Prevention of Pentylenetetrazole-Induced Kindling and Behavioral Comorbidities in Mice by Levetiracetam Combined with the GLP-1 Agonist Liraglutide: Involvement of Brain Antioxidant and BDNF Upregulating Properties","volume":"109","author":"Lopes","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.npep.2010.02.002","article-title":"Effects of Centrally-Injected Glucagon-like Peptide-1 on Pilocarpine-Induced Seizures, Anxiety and Locomotor and Exploratory Activity in Rat","volume":"44","author":"Gulec","year":"2010","journal-title":"Neuropeptides"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ahn, Y.-J., Shin, H.-J., Jeong, E.-A., An, H.-S., Lee, J.-Y., Jang, H.-M., Kim, K.-E., Lee, J., Shin, M.-C., and Roh, G.-S. (2021). Exendin-4 Pretreatment Attenuates Kainic Acid-Induced Hippocampal Neuronal Death. Cells, 10.","DOI":"10.3390\/cells10102527"},{"key":"ref_29","first-page":"417","article-title":"Antiepileptic Effects of Exenatide in Penicillin Induced Acute Epilepsy Model in Rats","volume":"61","author":"Yildiz","year":"2023","journal-title":"Indian J. Exp. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11064-022-03736-4","article-title":"The Anti-Seizure Effect of Liraglutide on Ptz-Induced Convulsions Through Its Anti-Oxidant and Anti-Inflammatory Properties","volume":"48","author":"Erdogan","year":"2023","journal-title":"Neurochem. Res."},{"key":"ref_31","first-page":"752","article-title":"Anticonvulsant Effect of Liraglutide, GLP-1 Agonist by Averting a Change in GABA and Brain Glutathione Level on Picrotoxin-Induced Seizures","volume":"16","author":"Gupta","year":"2017","journal-title":"EXCLI J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainresbull.2018.06.017","article-title":"The Role of the GLP-1\/GLP-1R Signaling Pathway in Regulating Seizure Susceptibility in Rats","volume":"142","author":"Zhang","year":"2018","journal-title":"Brain Res. Bull."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eplepsyres.2018.03.009","article-title":"Post-Treatment with the GLP-1 Analogue Liraglutide Alleviate Chronic Inflammation and Mitochondrial Stress Induced by Status Epilepticus","volume":"142","author":"Wang","year":"2018","journal-title":"Epilepsy Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Antmen, F.M., Fedaioglu, Z., Acar, D., Sayar, A.K., Yavuz, I.E., Ada, E., Karakose, B., Rzayeva, L., Demircan, S., and Kardouh, F. (2024). Exploring Liraglutide in Lithium-Pilocarpine-Induced Temporal Lobe Epilepsy Model in Rats: Impact on Inflammation, Mitochondrial Function, and Behavior. Biomedicines, 12.","DOI":"10.3390\/biomedicines12102205"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.eplepsyres.2019.05.008","article-title":"The Novel GLP-1\/GIP Dual Receptor Agonist DA3-CH Is Neuroprotective in the Pilocarpine-Induced Epileptogenesis Rat Model","volume":"154","author":"Tian","year":"2019","journal-title":"Epilepsy Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E472","DOI":"10.1152\/ajpendo.00250.2023","article-title":"Brain Access of Incretins and Incretin Receptor Agonists to Their Central Targets Relevant for Appetite Suppression and Weight Loss","volume":"326","author":"Buller","year":"2024","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"745613","DOI":"10.1155\/2015\/745613","article-title":"Seizure-Induced Oxidative Stress in Temporal Lobe Epilepsy","volume":"2015","author":"Puttachary","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1212\/WNL.0000000000216104","article-title":"Semaglutide Concentration in Cerebrospinal Fluid from Patients with Early Alzheimer\u2019s Disease After 12 Weeks of Subcutaneous Treatment (P3-13.012)","volume":"106","author":"Alford","year":"2026","journal-title":"Neurology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/ijo.2015.136","article-title":"Transfer of Liraglutide from Blood to Cerebrospinal Fluid Is Minimal in Patients with Type 2 Diabetes","volume":"39","author":"Christensen","year":"2015","journal-title":"Int. J. Obes."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide Lowers Body Weight in Rodents via Distributed Neural Pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"123688","DOI":"10.1016\/j.jchromb.2023.123688","article-title":"Novel LC-MS\/MS Analysis of the GLP-1 Analog Semaglutide with Its Application to Pharmacokinetics and Brain Distribution Studies in Rats","volume":"1221","author":"Lee","year":"2023","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.semcdb.2014.10.003","article-title":"Blood-Brain Barrier Dysfunction, Seizures and Epilepsy","volume":"38","author":"Aronica","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e218174","DOI":"10.1212\/WNL.0000000000218174","article-title":"Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation","volume":"107","author":"Eun","year":"2026","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the Effectiveness and Risks of GLP-1 Receptor Agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.70022","article-title":"Seizure Recurrence after GLP-1 Receptor Agonist Initiation in Adults with Epilepsy","volume":"67","author":"AbuAlrob","year":"2026","journal-title":"Epilepsia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10309-026-00835-y","article-title":"Semaglutide-Induced Status Epilepticus: A Positive Rechallenge Case Report","volume":"39","author":"Findeis","year":"2026","journal-title":"Clin. Epileptol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/epi4.13091","article-title":"Newer Glucose-Lowering Drugs Reduce the Risk of Late-Onset Seizure and Epilepsy: A Meta-Analysis","volume":"9","author":"Sindhu","year":"2024","journal-title":"Epilepsia Open"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"18063","DOI":"10.1038\/s41598-025-01206-9","article-title":"Pharmacovigilance Analysis of Neurological Adverse Events Associated with GLP-1 Receptor Agonists Based on the FDA Adverse Event Reporting System","volume":"15","author":"Chen","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40264-023-01392-3","article-title":"Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review","volume":"47","author":"Calvarysky","year":"2024","journal-title":"Drug Saf."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8036\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:15:57Z","timestamp":1789100157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":49,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188036"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188036","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}